Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Only 26K shares short ....as of Monday 14th....

<< Previous

Bullboard Posts

Next >>

Comment by clubhouse19on Dec 21, 2020 10:24am

110 Views

Post# 32152162

RE:RE:Only 26K shares short ....as of Monday 14th....

There was over 120k shares shorted between dec1 and dec 15

What will be interesting is to see the shorted activity ending dec 31...I thinkl there will be quite a rise.
the o/s short position really means squat to the brothel of bay street.

MrMugsy wrote:

MasterAlgae wrote:

https://www.iiroc.ca/industry/marketmonitoringanalysis/Pages/consolidated-short-position-report.aspx

That's about 0.067 % of outstanding shares ... almost nothing.